Results

MeCP2 Occupies Unique Sites In Vivo
In order to identify genomic loci occupied by MeCP2 in vivo, we performed chromatin immunoprecipitation (ChIP) with MeCP2-specific antibodies. We chose to study the MRC-5 human lung embryonic fibroblast cell line, as it displays characteristics of untransformed cells and has a normal diploid karyotype. At least three methyl-CpG binding proteins, MeCP2, MBD2, and MBD1, are detectable in nuclear extracts of MRC-5 cells (data not shown). To identify specific DNA sites bound by MeCP2, we used a "ChIP-and-clone" approach. Growing MRC-5 cells were formaldehyde fixed, and isolated chromatin was sonicated to generate DNA fragments of 250-750 bp. MeCP2-associated chromatin was then immunoprecipitated with MeCP2-specific antibodies, recovered, and adaptor sequences added. Primers complementary to the adaptor sequences were used to amplify DNA fragments, which were then cloned, and 98 plasmids were sequenced. As a control for random effects, sonicated genomic DNA was also cloned and sequenced (Tables S1 and  S3 available in the Supplemental Data with this article  online) . Blast analysis indicated that 57% of MeCP2 binding sites mapped to intergenic sequences and 28% to introns and exons within annotated genes (Tables S1 and S3).
To ensure that the recovered loci were genuine MeCP2 targets, we repeated the ChIP but assayed with primers that were specific for each of 24 representative single-copy sequences from the first experiment (Figure 1A and Figure S1C ). MeCP2 was reproducibly immunoprecipitated at loci identified in the initial ChIPand-clone screen but rarely (one out of 18 fragments tested) at loci recovered from cloning of random genomic DNA ( Figure S1B ). When cells were pretreated with 5-azacytidine, the MeCP2 ChIP signal was lost, demonstrating that binding is dependent on DNA methylation ( Figure 1A , lanes MeCP2*). Bisulfite sequencing of eight of these loci independently confirmed that all these sites contain highly methylated CpGs in MRC-5 cells ( Figure S2) . Surprisingly, ChIP of the same fixed chromatin sample with antibodies against MBD1 and MBD2 ( Figure 1A) showed that only one of 12 MeCP2 bound fragments was immunoprecipitated by the anti-MBD2 antibody, and none were precipitated by anti-MBD1 antibody. We conclude that in these primary human cells, MeCP2 binds to unique loci that, for the most part, do not attract the MBD2 and MBD1. Figure 1C and Figure S1C ). In MeCP2-deficient cells, 13 of the 24 tested loci were now bound by MBD2.
MBD2 Can
Having established that MBD2 could colonize methylated sites vacated by MeCP2, we next asked the converse question: could MeCP2 move into sites vacated by MBD2? To address this, we isolated loci from the MRC-5 genome that were bound by MBD2 using the ChIP-and-clone methodology. Cloned loci were sequenced, located on the human genome sequence assembly (Tables S2 and S3) , and verified by PCR amplification of an independent MBD2 ChIP fraction using locus-specific primers ( Figure S1A ). To determine if these loci could be colonized by MeCP2, we depleted MBD2 in MRC-5 cells, again using a morpholino approach ( Figure 1B ). After two sequential transfections with MBD2 morpholino (MBD2-MO), MBD2 protein was undetectable in nuclear extracts from these cells. The effect was specific, as levels of MeCP2 or the unrelated protein PCNA were unaltered. As expected, depletion of MBD2 greatly reduced the recovery of MBD2-associated loci by ChIP with anti-MBD2 antibodies ( Figure 1D and Figure S1D ). Only five of the 25 loci gave a residual signal, whereas fragments were recovered normally after treatment with a mismatched morpholino (MBD2-mis-MO) that had no effect on MBD2 abundance. To assess whether MeCP2 was able to take over MBD2 sites, ChIP experiments were carried out in parallel on the MBD2-MO-treated samples by using MeCP2-specific antibodies. Depletion of MBD2 resulted in MeCP2 occupancy at only three of the 25 sites vacated by MBD2. These data indicate that MeCP2 is reluctant to replace MBD2. using one of these sequences (S5) showed low affinity for MeCP2, suggesting that this was a contaminant ( Figure 3C ).
Enrichment of MeCP2 Binding
To directly test the importance of the A/T-rich sequences for MeCP2 binding, we placed C/G pairs within the A/T runs of fragments S1 and S3 by mutagenesis ( Figure 4A ). In each case, the mutations drastically reduced the MeCP2 binding affinity of these probes to levels seen in unselected DNA ( Figure 4B ). As all probes were methylated at a fixed central CCGG, we Figure 5A ). We asked whether the AT hook might be responsible for the A/T run-dependent binding of MeCP2 by mutating two conserved arginine amino acids within the MeCP2 AT hook to glycine (Figure 5A) . Equivalent mutations within the AT hook of HMGA1 significantly inhibited the recovery of binding to heterochromatin in photobleaching experiments (Harrer et al., 2004). When wt and mutant MeCP2 proteins were assayed by EMSA for binding to the S1 and S1-mutated DNA fragments, however, we were surprised to find that loss of the AT hook domain had no effect on the affinity or specificity of MeCP2 for probes that contained an A/ T run ( Figure 5B Figure 7E) . To test the efficiency of MeCP2 binding to this sequence, we generated a probe (−148) corresponding to the MeCP2 binding site and a control probe containing one CpG from within Bdnf exon 1 (Figures 7D and 7E) . The −148 sequence bound MeCP2 by EMSA as predicted, and the control fragment showed no obvious binding ( Figure 7F) . Mutation of the A/T runs adjacent to −148 greatly reduced binding to MeCP2. It is notable that the sequence corresponding to the Bdnf site (5#-CGGAATT-3#) occurred (Figure 7G) . These data suggest that MeCP2 binding at this regulatory region is orientated with respect to the methyl-CpG through interaction with the adjacent AT-run. Focusing on MBD2 and MeCP2, we asked whether removal of one protein would allow the other protein to take over the vacant sites. We found that the answer varied according to which protein was depleted. MBD2 was able to occupy many of the sites vacated by MeCP2 (13 out of 24), but MeCP2 was markedly less promiscuous, occupying only three out of 24 ex-MBD2 sites. This difference could potentially be explained in several ways, but we followed up the simple hypothesis that MeCP2 is tied to a subset of methyl-CpGs through a requirement for additional DNA sequence at its binding site. The speculation proved correct, as high- et al., 1995) . These findings might be explained if GGTGT represents a weak mimic of methyl-CpG, whose affinity for MeCP2 can be strengthened by a flanking run of A/T DNA. Given the current lack of evidence that MeCP2 binds nonmethylated DNA in vivo, the biological relevance of its putative DNA methylation-independent binding remains uncertain.
Experimental Procedures
Cell Culture MRC-5 cells were cultured in MEM supplemented with 10% fetal calf serum, nonessential amino acids, sodium pyruvate, and antibiotics (Gibco). NIH3T3 cells were cultured in DMEM with 10% newborn calf serum, and p53 −/− cells were cultured in DMEM supplemented with 10% newborn calf serum, nonessential amino acids, sodium pyruvate, and antibiotics (Gibco).
Chip and Clone
Chip-and-clone experiments were carried out as described previously (Sarraf and Stancheva, 2004) 
Morpholino Transfections
MeCP2 and MBD2 morpholinos and control five-mismatch morpholino oligos were designed by and purchased from Gene Tools LLC (sequences available upon request). MRC-5 cells were transfected in T25 flasks according to the manufacturer's instructions, grown for 3 days, transferred into T75 flasks, transfected again, and left to grow for an additional 3 days. The cells from the first and the second round of transfection were collected, and nuclear extracts prepared according to the standard protocols and analyzed by Western blotting.
Expression of Recombinant MeCP2 and MBD2
Recombinant proteins were expressed in bacteria as described previously (Klose and Bird, 2004). All MeCP2 and MBD2 recombinant protein expression vectors were constructed in the same manner containing a C-terminal histidine tag to facilitate purification.
Methyl-SELEX, EMSA, and DNase I Footprinting
Detailed protocols for Methyl-SELEX, EMSA, and DNase I footprinting are available in the Supplemental Data online. 
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